Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Inspire Medical Systems Earnings Call: Key Takeaways

Inspire Medical reported a 7.9% year-over-year revenue decline due to $120 million in coding headwinds, while focusing on a 2027 return to growth.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthUS revenue up 3% sequentially; International revenue down 9% in Q3.
Mgmt ConfidenceIncreasingly confident in 2027 return to growth as coding stabilizes.
Demand VisibilityTracking $120 million impact from coding; patient funnel remains active.
Margin TrendsGross margin 86%, up 20bps; adjusted operating margin 4.5% to 5.5%.
Op. LeverageProject Horizon created $30 million annualized growth investment capacity.
Pricing PowerInspire 5 carries higher gross margin than Inspire 4.
Vol vs PriceGrowth driven by Inspire 5 adoption; volume impacted by coding changes.
Segment GrowthInspire 5 now makes up the vast majority of procedures.
New ClientsAdding field roles in 40 high-potential growth markets to improve flow.
Capex & DebtNo debt; $453.1M cash; Capex $35M-$40M; $24.1M restructuring charges.
RegulatoryCategory 1 CPT code approved for January 1, 2028 effective date.
CommentaryShifting focus from coding stabilization to optimizing patient flow and cardiology referrals.
New LaunchesInspire 6 development targeting FDA submission in 2027.

Growth

Q3 revenue $206.7M, down 7.9% YoY; US outperformed while International declined 9%.

Outlook

Guiding to low single-digit revenue growth for full year 2027.

Risks

Management pivoted to vague language regarding specific 2027 market growth rates and competitor impact.

Source

The company's earnings call, NYSE: INSP, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Inspire Medical Systems, Inc.: key numbers

Share price
$59.12Close, Nov 16
Market cap
$1.71B
Shares outstanding
28.97MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Inspire Medical Systems, Inc.

All →
4:32 PM ET 10-Q
Financial Results ▶ Call

Inspire Medical Systems Q3 2026 Results: Net Loss of $24.4M

For the nine months ended September 30, 2026, Inspire Medical Systems reported a net loss of $35.4 million on revenue of $611.9 million, compared to a net profit of $9.3 million in the prior year period. The shift to a loss was driven by a decrease in revenue and a significant increase in selling, general, and administrative expenses.

Key figure
Net loss $24.4M
4:30 PM ET 8-K
Financial Results

Inspire Medical Systems Financial Results

Inspire Medical Systems reported Q3 2026 revenue of $206.7 million, a 7.9% decrease year-over-year primarily due to U.S. coding and reimbursement challenges. Despite the revenue decline, the company achieved a positive adjusted diluted EPS of $0.14 and noted that the AMA approved new Category I CPT codes for its Inspire V system effective 2028.

Term
3 months

“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic.”

Tim Herbert, Chairman and CEO of Inspire Medical Systems

“Looking further ahead, we were also pleased with the AMA Editorial Panel’s September approval of a new CPT® code for single lead HGNS devices, including the Inspire V system. When this takes effect in January 2028, a dedicated code set will give physicians and hospitals enhanced clarity around coding and reimbursement and, in turn, further enable patient access to Inspire therapy.”

Tim Herbert, Chairman and CEO of Inspire Medical Systems

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.